Active Surveillance

Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered

Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered

By

Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.

Disease-Specific Mortality Comparable Among Treatment Options for Prostate Cancer

By

Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.

Predictors Identified for Switching to Active Treatment in Prostate Cancer

Predictors Identified for Switching to Active Treatment in Prostate Cancer

Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance

Opting for Active Surveillance Increasing Among Men With Low-grade Prostate Cancer

By

Patients with slow-growing prostate cancer are increasingly opting for active surveillance and only changing treatment plan if the disease changes to a higher risk form to avoid unnecessary and potentially toxic treatments.

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

By

African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.

Dose-escalated radiation does not benefit patients with low-risk prostate cancer

Dose-escalated radiation does not benefit patients with low-risk prostate cancer

Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

By

An analysis of data on 945 patients with prostate cancer followed with active surveillance displayed outcome differences, depending on whether the patient was low- or intermediate-risk at diagnosis.

Study may support active surveillance for favorable intermediate-risk prostate cancer

By

New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.

Active surveillance of prostate cancer leads to improved quality of life

Active surveillance of prostate cancer leads to improved quality of life

Active surveillance allows men with prostate cancer to delay or avoid the side effects of its treatment as well.

Three-gene test can identify which prostate cancers require treatment

By

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to new research.

Prostate cancer grade usually does not progress over time

By

The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.

Targeted biopsy detects more prostate cancers

A clinic-based technique of targeted biopsy using MRI and ultrasound may improve the diagnosis and management of prostate cancer.

Active surveillance is viable alternative to surgery for small kidney masses

By

Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery. The overall and cancer specific survival rates are similar for both approaches.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs